Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period : Findings from the PSERENADE Project
- PSERENADE Team
- Quesada, Maria Garcia
- Yang, Yangyupei
- Bennett, Julia C.
- Hayford, Kyla
- Zeger, Scott L.
- Feikin, Daniel R.
- Peterson, Meagan E.
- Cohen, Adam L.
- Almeida, Samanta C.G.
- Ampofo, Krow
- Ang, Michelle
- Bar-Zeev, Naor
- Bruce, Michael G.
- Camilli, Romina
- Chacón, Grettel Chanto
- Ciruela, Pilar
- Cohen, Cheryl
- Corcoran, Mary
- Dagan, Ron
- De Wals, Philippe
- Desmet, Stefanie
- Diawara, Idrissa
- Gierke, Ryan
- Guevara, Marcela
- Hammitt, Laura L.
- Hilty, Markus
- Ho, Pak Leung
- Jayasinghe, Sanjay
- Kleynhans, Jackie
- Kristinsson, Karl G.
- Ladhani, Shamez N.
- McGeer, Allison
- Mwenda, Jason M.
- Nuorti, J. Pekka
- Oishi, Kazunori
- Ricketson, Leah J.
- Sanz, Juan Carlos
- Savrasova, Larisa
- Setchanova, Lena Petrova
- Smith, Andrew
- Valentiner-Branth, Palle
- Valenzuela, Maria Teresa
- van der Linden, Mark
- van Sorge, Nina M.
- Varon, Emmanuelle
- Winje, Brita A.
- Yildirim, Inci
- Zintgraff, Jonathan
- Knoll, Maria Deloria
DOIAbstract
Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% i...
Add to ORKG